Loading...

Please wait

पॉडकास्ट

लोड हो रहा है...

OndaCast© 2026 OndaCast. सर्वाधिकार सुरक्षित।

सहायता संपर्क शर्तें गोपनीयता कॉपीराइट DMCA बारे में रेडियो गाइड प्लेयर एम्बेड करें

Waves Explore Library Vibes Podcasts Audiobooks

Decera Clinical Education Oncology Podcast - Podcast | OndaCast

पॉडकास्ट

पॉडकास्ट पर वापस जाएं

पॉडकास्ट शोपॉडकास्टen

Decera Clinical Education Oncology Podcast

द्वाराDecera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

219 एपिसोड•0 सदस्य•0 कुल सुनने वाले

एपिसोड प्लेलिस्ट

50 एपिसोड

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

May 14, 2024•—

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Jul 5, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Congress to Clinic: Expert Takeaways on Emerging Data for AML

Jul 8, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for AML

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Jul 9, 2024•—

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Jul 11, 2024•—

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

Jul 12, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

Current Clinical Practice and NCCN Guidelines for CLL/SLL

Jul 18, 2024•—

Current Clinical Practice and NCCN Guidelines for CLL/SLL

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Jul 22, 2024•—

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Aug 5, 2024•—

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

ROS1-Alterations and Molecular Testing in Advanced NSCLC

Aug 28, 2024•—

ROS1-Alterations and Molecular Testing in Advanced NSCLC

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Sep 5, 2024•—

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

Sep 6, 2024•—

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Sep 30, 2024•—

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Oct 1, 2024•—

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

Oct 16, 2024•—

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

$Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies$

Oct 22, 2024•—

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Jan 9, 2025•—

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

$Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting$

Feb 10, 2025•—

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Feb 20, 2025•—

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

Mar 25, 2025•—

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Apr 21, 2025•—

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Apr 24, 2025•—

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies

May 5, 2025•—

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications

May 16, 2025•—

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications

May 29, 2025•—

Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Experts Discuss CELMoDs in Myeloma

Jul 15, 2025•—

Experts Discuss CELMoDs in Myeloma

Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies

Jul 18, 2025•—

Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

Jul 18, 2025•—

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

Jul 23, 2025•—

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Jul 24, 2025•—

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

Jul 25, 2025•—

Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Jul 25, 2025•—

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Jul 28, 2025•—

Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective

Aug 12, 2025•—

Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

Aug 15, 2025•—

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

Aug 26, 2025•—

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

Sep 3, 2025•—

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients

Sep 4, 2025•—

Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients

Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma

Sep 11, 2025•—

Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

Oct 13, 2025•—

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer

Oct 14, 2025•—

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Oct 14, 2025•—

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Oct 28, 2025•—

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care

Oct 31, 2025•—

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

Nov 5, 2025•—

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

Nov 6, 2025•—

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

Nov 18, 2025•—

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting

Dec 17, 2025•—

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

Dec 18, 2025•—

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

Dec 19, 2025•—

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

आपको ये भी पसंद आ सकते हैं

OndaCast© 2026 OndaCast. सर्वाधिकार सुरक्षित।

सहायता संपर्क शर्तें गोपनीयता कॉपीराइट DMCA बारे में रेडियो गाइड प्लेयर एम्बेड करें

Waves Explore Library Vibes Podcasts Audiobooks